ICER recently announced a partnership with Aetion. ICER will use Aetion’s RWE (real world evidence) in revising its assessment on treatments for hereditary angioedema. This pilot study could be the first of many reports utilizing RWE and RWD (real world data). This collaboration and subsequent reports is expected to be closely followed by pharma, payers, and other healthcare professionals.
“Aetion believes project will help ‘pressure test’ the RWE field and show health plans and providers the value of using real world evidence to supplement clinical trial data.” Read more here.
(Source: Pink Sheet, 4/12/21; ICER, 4/12/21)